ribosomal protein L36 pseudogene 2Genealiases: RPL36_8_1711 · dJ530I15.5
Q-omics provides the consensus-scored RPL36P2 profile across patient tissues and cancer cell-line models. RPL36P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL36P2 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, RPL36P2 RNA expression shows 6,593 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRP, LUSC, and UCEC as cancer lineages where RPL36P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36P2 survival associations across molecular data types. RPL36P2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36P2 RNA expression–survival associations across cancer types. High RPL36P2 expression shows unfavorable associations in LUSC, TGCT, ACC, MESO and CHOL, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL36P2 RNA expression.
This table summarizes RPL36P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36P2 shows lower tumor expression in LUSC, KICH and LUAD and higher tumor expression in ESCA and COAD. The LUSC box plot shows higher RPL36P2 RNA expression in normal versus tumor tissue (log2 FC = −0.222, t-test p < 0.001).
This table shows molecular features associated with RPL36P2 in patient tissues and cancer cell lines. In patient samples, RPL36P2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
